Note:

Professor Christopher Nutting

Clinical oncology, Medical oncology

About me

I am a specialist in Radiotherapy and Chemotherapy with a particular interest in reducing side effects of treatment by using highly focussed radiotherapy. I am a leader in treatment of head and neck and thyroid cancers as well as lung cancer.
Our advances in IMRT led to the RMH and ICR winning the prestigious 2013 Quality In Care In Oncology Awards for improving the quality of life for people living with cancer.

Current NHS consultant posts held

Royal Marsden Hospital, Chelsea and Sutton

Research interests

I firmly believe that the future of improving outcomes in cancer treatment is through well-designed clinical research.

In collaboration with the Institute of Cancer Research (ICR), I led my team at the Royal Marsden Hospital in developing and refining Intensity-Modulated Radiotherapy (IMRT) which reduces side-effects of radiotherapy treatment by avoiding healthy tissue around the tumour site.

Personal interests

I enjoy running and other sports and spending time with my family

Awards received

Silver Clinical Excellence Award by the NHS in 2015

Quality In Care In Oncology Award for improving the quality of life for people living with cancer, 2013 (team award)

Royal College of Radiologists/IPEM Cochrane-Shanks-Jalill Visiting Professorship Cluj-Napocou, Romania, 2010

(Additional) Languages spoken

Italian

Publications

I have written over 150 scientific papers cited in the medical literature. There are the top 5:

Papers on IMRT implementation, culminating in the PARSPORT trial

1. Mehanna H, et al: Epidemiology, presentation, and prevention. BMJ. 2010 Sep 20;341:
Prof Nutting commissioned to lead on a BMJ head and neck cancer review.
2. Clark CH, et al; PARSPORT Trial Management Group. Dosimetry audit for a multi-centre IMRT head and neck trial. Radiother Oncol. 2009 Oct;93(1):102-8.
This paper describes a National dosimetry audit for the PARPORT trial. The first time that National QA had been performed for a head and neck IMRT trial in the World
3. Guerrero Urbano MT, et al, PARSPORT Trial Management Group. Target volume definition for head nd neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines. Clin Oncol (R Coll Radiol). 2007;19:604-13.
This key publication details the comprehensive target volume definition guidelines for parotid sparing IMRT for the PARSPORT trial. No similar multi-centre National consensus has been published in the literature
4. Nutting CM, et al on behalf of the PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and Neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011 Jan 12.
This was the first reported results of a randomised controlled trial of parotid sparing IMRT demonstrating improvements in patient reported xerostomia, increased saliva production and improvements in global quality of life. This trial is the only RCT in squamous cell carcinoma of the head and neck and has contributed to IMRT becoming the standard of care around the World
5. Miles, E.A., et al., The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol, 2005. 77(3): p. 241-6.
This paper described the impact of introducing IMRT into clinical practice. It was used by the National Cancer Action Team to calculate the impact and cost of a National IMRT implementation after the publication of the PARSPORT trial

Courses offered to GPs

I participate in Local, National and International lectures to general practitioners and specialists around the world
I am currently involved in the installation of one of Britain’s first MR Linac machines at RMH. This offers to revolutionise cancer treatment by combining a scanner to precisely locate the tumour and an accelerator to accurately deliver radiation at the same time.

View photos of my work

Outcomes (self-reported)

In patient satisfaction surveys performed for my annual appraisal, I scored excellent by over 95% of patients.
I have published the outcomes of my cancer treatments in the peer reviewed literature. The results published are amongst the best in the World literature.

The information contained on Finder is submitted by consultants, therapists and facilities, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the data and information on Finder and our website terms of use here.